You are here

psoriasis

UCB posts more supportive data from Humira rival bimekizumab

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Flag link:

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Fierce Pharma

Flag link:

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Endpoints

clinical trials

Flag link:

Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

Fierce Pharma

psoriatic arthritis

clinical trials

Flag link:

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

BioSpace

clinical trials

Flag link:

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

Fierce Biotech

bispecific antibodies

Flag link:

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

Endpoints

Flag link:

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

BioSpace

Sienna Biopharmaceuticals

Flag link:

Skyrizi looks ready to soar after strong launch

Skyrizi looks ready to soar after strong launch

Biopharma Dive

Flag link:

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Stat

Bristol-Myers Squibb

Flag link:

5 Biggest New Drugs Approved in 2019 So Far

5 Biggest New Drugs Approved in 2019 So Far

Motley Fool

multiple sclerosis

metastatic bladder cancer

Flag link:

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Fierce Pharma

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Fierce Pharma

Flag link:

Ramaswamy's Dermavant Updates $124 Million IPO Filing

Ramaswamy's Dermavant Updates $124 Million IPO Filing

CP Wire

Vivek Ramaswamy

Flag link:

Ramaswamy's Dermavant Updates $124 Million IPO Filing

Flag link:

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Flag link:

AbbVie successor to Humira in psoriasis gains FDA approval

AbbVie successor to Humira in psoriasis gains FDA approval

BioCentury

Flag link:

AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales

AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales

Endpoints

Flag link:

AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval

AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval

Fierce Pharma

psoriatic arthritis

Flag link:

Pages